Understanding Chronic Obstructive Pulmonary Disease Management and Treatment Patterns in General Medicine: Results From the ASTER Study in Italy
International Journal of Chronic Obstructive Pulmonary Disease · 2025
DOI: 10.2147/copd.s517556 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Gino Genga und 6 weiteren Autor:innen. Beteiligte Einrichtung: ASUR, Area Vasta 1, Distretto di Fano, Italy. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones, Adrenergic beta-2 Receptor Agonists, Bronchodilator Agents, General Practice. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: COPD
Abstract (Originalsprache)
Purpose
The ASTER study described the management of chronic obstructive pulmonary disease (COPD) by general practitioners (GPs) in Italy, focusing on the treatment patterns and clinical outcomes of patients over 6 months. Patients and Methods: This multicenter prospective cohort study included patients aged 40-80 years with spirometry-confirmed COPD, post-bronchodilator FEV1 ≥50% of predicted value, and ≤1 exacerbation in the previous year. Eligible patients had a COPD assessment test (CAT) score of ≥10 and, according to the prescription limits for GPs before Note 99, they could have been treated in the last 3 months before enrollment exclusively with a short or long acting bronchodilator or an corticosteroid/long-acting beta2-agonist ICS/LABA. Patients were evaluated at enrollment, 3 months, and 6 months, with data collected on treatment, exacerbations, patient-reported outcomes (CAT and mMRC scores), and lung function.
Results
Overall, 385 patients were enrolled, and 344 (89.4%) met the study criteria, of which 332 (96.5%) completed the study. The cohort included patients with mild to moderate COPD, predominantly males (61.9%), and current/former smokers (91%). At baseline, ongoing treatments included LAMA (20.9%), ICS/LABA (13.7%), and LABA (2.9%). However, 62.5% of patients were not treated. By 6 months, only 10.2% of patients were not receiving any treatment and 55.4% were treated with a LABA/LAMA combination. FEV1 showed a mean increase of 140 mL, mMRC ≥ 2 decreased from 54.9% to 23.5%, CAT exhibited a 3.6 point mean decrease, and only 13 patients (3.9%) experienced mild/moderate exacerbations in the last 6 months.
Conclusion
ASTER study highlights the effectiveness of COPD treatment by GPs in Italy. Early detection and proactive management, along with a regular treatment prescription was associated with improved lung function, dyspnea, quality of life, and a reduction in the incidence of exacerbations. Empowering GPs with diagnostic and therapeutic responsibilities, improves care and outcomes of COPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ASUR, Area Vasta 1, Distretto di Fano, Italy.
- ASP 5, Messina, Italy.
- Medical Affairs, GSK, Verona, Italy.
- Catholic University, Roma, Italy.
Zitieren
APA
Genga, G., Alecci, U., Vighini, M., Stabile, C., Cinquepalmi, D., Grassi, B., & Pistelli, R. (2025). Understanding Chronic Obstructive Pulmonary Disease Management and Treatment Patterns in General Medicine: Results From the ASTER Study in Italy. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s517556
Vancouver
Genga G, Alecci U, Vighini M, Stabile C, Cinquepalmi D, Grassi B, et al. Understanding Chronic Obstructive Pulmonary Disease Management and Treatment Patterns in General Medicine: Results From the ASTER Study in Italy. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s517556
BibTeX
@article{Genga2025,
author = {Genga, Gino and Alecci, Umberto and Vighini, Miriam and Stabile, Carmen and Cinquepalmi, Donato and Grassi, Barbara and Pistelli, Riccardo},
title = {Understanding Chronic Obstructive Pulmonary Disease Management and Treatment Patterns in General Medicine: Results From the ASTER Study in Italy},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2025},
doi = {10.2147/copd.s517556}
}
EUVIMED